Drugs / STI-1558
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05754411 | May → Jun 2023 | COVID-19 | Zhejiang ACEA Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05685719 | Jan → Mar 2023 | pneumonia | Zhejiang ACEA Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05716425 | Feb → Jul 2023 | COVID-19 | Zhejiang ACEA Pharmaceutical Co. Ltd. | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STI-1558 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05754411 ↗ |
| Known as | olgotrelvir | “Olgotrelvir (STI-1558) is designed as a next-generation antiviral targeting the SARS-CoV-2 main protease (Mpro), an essential enzyme for SARS-CoV-2 replication, and human...” PMID 38181791 ↗ Jan 2024 |
| Action | Inhibit | “effectively inhibits the SARS-CoV-2 main protease (Mpro).” NCT05685719 ↗ |
| Modality | Small molecule | “An oral small molecule prodrug” NCT05685719 ↗ |
| Route | Oral | “An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).” NCT05685719 ↗ |
| Target | CTSL | “Olgotrelvir (STI-1558) is designed as a next-generation antiviral targeting the SARS-CoV-2 main protease (Mpro), an essential enzyme for SARS-CoV-2 replication, and human...” PMID 38181791 ↗ Jan 2024 |